title: The mechanism of action for oxyntomodulin in the regulation of obesity.
abstract: Oxyntomodulin, a product of the proglucagon gene, is released from the enteroendocrine L-cells of the gastrointestinal tract after the digestion of food, and acts via glucagon-like peptide 1 receptors in the arcuate nucleus to induce satiety. The administration of oxyntomodulin to animals and humans causes weight loss by reducing food intake in combination with increasing energy expenditure. Thus, the development of potent and long-acting analogs of oxyntomodulin is an exciting new therapeutic avenue for addressing the global obesity epidemic. This review discusses the role of oxyntomodulin in the physiological control of appetite, and presents the currently available evidence suggesting its potential as an obesity treatment.
authors.affiliation: Imperial College London, Department of Metabolic Medicine, Hammersmith Hospital, UK.
authors.forename: Katie
authors.initials: K
authors.lastname: Wynne
authors.forename: Benjamin Ct
authors.initials: BC
authors.lastname: Field
authors.forename: Stephen R
authors.initials: SR
authors.lastname: Bloom
mesh_terms: D000818:Animals; D001067:Appetite Depressants / Q000494:pharmacology* / Q000627:therapeutic use*; D001069:Appetite Regulation / Q000187:drug effects; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D004435:Eating / Q000187:drug effects / Q000502:physiology; D004734:Energy Metabolism / Q000187:drug effects; D019858:Enteroendocrine Cells / Q000378:metabolism / Q000502:physiology; D041981:Gastrointestinal Tract / Q000378:metabolism; D005934:Glucagon / Q000378:metabolism; D004763:Glucagon-Like Peptides / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D009765:Obesity / Q000188:drug therapy*; D053772:Oxyntomodulin / Q000494:pharmacology* / Q000627:therapeutic use*
chemical_list: D001067:Appetite Depressants; D053772:Oxyntomodulin; D004763:Glucagon-Like Peptides; D005934:Glucagon